The UK Patents Act 1977, in line with the WTO TRIPS Agreement, provides for compulsory licenses in certain circumstances.<\/p>
<\/p>
Kadcyla (trastuzumab emtansine) is currently available to patients in England for the treatment of HER2-positive locally advanced, unresectable or metastatic breast cancer through the Cancer Drugs Fund.<\/p>
<\/p>
The National Institute for Health and Care Excellence (NICE) is currently reviewing its technology appraisal guidance on trastuzumab emtansine for refractory, HER2 positive breast cancer. NICE expects to publish its updated guidance in February 2017.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4039", "label" : {"_value" : "Biography information for Lord Johnson of Marylebone"} } , "answeringMemberConstituency" : {"_value" : "Orpington"} , "answeringMemberPrinted" : {"_value" : "Joseph Johnson"} , "dateOfAnswer" : {"_value" : "2016-11-04", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2016-11-04T14:03:54.493Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "201"} , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "date" : {"_value" : "2016-11-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Intellectual Property: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what his Department's policy is on using the flexibility provided by the Trade Related Aspects of Intellectual Property Rights under World Trade Organisation rules for compulsory license for the Kadcyla form of trastuzumab emtansine for UK patients.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4433", "label" : {"_value" : "Biography information for Thangam Debbonaire"} } , "tablingMemberConstituency" : {"_value" : "Bristol West"} , "tablingMemberPrinted" : [{"_value" : "Thangam Debbonaire"} ], "uin" : "51439"} , {"_about" : "http://data.parliament.uk/resources/620974", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/620974/answer", "answerText" : {"_value" : "
The Government is committed to maintain and enhance the strength of our research base. This is why we have protected the science resource budget in real terms from its 2015/16 level of £4.7 billion for the rest of the parliament, as well as committing to invest in new scientific infrastructure on a record scale \u2013 £6.9 billion over the period 2015-2021.<\/p>
<\/p>
The Treasury decision to underwrite the grants of competitively bid for EU research funding will give British participants and their EU partners the assurance and certainty needed to plan ahead for collaborative projects that can run over many years. We are committed to ensure that the UK continues to be a world leader in international science, including medical research into cancer.<\/p>
<\/strong><\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4039", "label" : {"_value" : "Biography information for Lord Johnson of Marylebone"} } , "answeringMemberConstituency" : {"_value" : "Orpington"} , "answeringMemberPrinted" : {"_value" : "Joseph Johnson"} , "dateOfAnswer" : {"_value" : "2016-11-07", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2016-11-07T17:40:22.88Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "201"} , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "date" : {"_value" : "2016-10-25", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cancer: Research"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what assessment he has made of the potential effect of the UK leaving the EU on research on rare and childhood cancers.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4433", "label" : {"_value" : "Biography information for Thangam Debbonaire"} } , "tablingMemberConstituency" : {"_value" : "Bristol West"} , "tablingMemberPrinted" : [{"_value" : "Thangam Debbonaire"} ], "uin" : "50081"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 2, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }